ストックスクリーナーアプリを入手
27.08
1.39%
0.37
プレマーケット:
27.01
-0.07
-0.26%
前日終値:
$26.71
開ける：
$26.98
24時間の取引高:
1.24M
Relative Volume:
0.81
時価総額：
$5.51B
収益：
-
当期純損益:
$-464.20M
株価収益率:
-10.10
EPS:
-2.6823
ネットキャッシュフロー:
$-423.09M
1週間 パフォーマンス:
-0.55%
1か月 パフォーマンス:
+7.67%
6か月 パフォーマンス:
+67.99%
1年 パフォーマンス:
+46.46%
1日の値動き範囲:
$26.60
$27.53
1週間の範囲:
$26.30
$28.27
52週間の値動き範囲:
$12.72
$29.25
Immunovant Inc Stock (IMVT) Company Profile
Compare IMVT vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
27.08 | 5.44B | 0 | -464.20M | -423.09M | -2.6823 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-06 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-10-14 | 開始されました | Truist | Hold |
| 2025-07-10 | 再開されました | Goldman | Neutral |
| 2025-03-03 | 開始されました | Jefferies | Hold |
| 2025-01-03 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-10-09 | 繰り返されました | Oppenheimer | Outperform |
| 2024-03-28 | 開始されました | Oppenheimer | Outperform |
| 2024-03-13 | 開始されました | Goldman | Buy |
| 2024-02-20 | 開始されました | JP Morgan | Overweight |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-10-13 | アップグレード | UBS | Neutral → Buy |
| 2023-09-26 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | 開始されました | BofA Securities | Buy |
| 2023-04-25 | 開始されました | Citigroup | Buy |
| 2023-03-31 | 開始されました | Piper Sandler | Overweight |
| 2023-03-30 | 開始されました | Stifel | Buy |
| 2023-02-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-02-13 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-01-03 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | ダウングレード | UBS | Buy → Neutral |
| 2021-12-08 | 開始されました | Wells Fargo | Equal Weight |
| 2021-08-03 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-06-01 | ダウングレード | Stifel | Buy → Hold |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-10-12 | 開始されました | Guggenheim | Buy |
| 2020-10-08 | 開始されました | Stifel | Buy |
| 2020-10-02 | 開始されました | Credit Suisse | Outperform |
| 2020-08-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-07-29 | 開始されました | H.C. Wainwright | Buy |
| 2020-02-24 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Immunovant Inc (IMVT) 最新ニュース
How Investors Are Reacting To Immunovant (IMVT) Narrower Q3 Loss and 2026 Autoimmune Trial Milestones - simplywall.st
Immunovant, Inc. (IMVT) Analysts Raise Price Targets Following Q3 Earnings Update - Finviz
Immunovant, Inc. (IMVT) Stock Analysis: A Compelling 48.2% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Immunovant (IMVT) COO executes 3,238-share sell-to-cover tax transaction - Stock Titan
Immunovant stock hits 52-week high at 28.32 USD By Investing.com - Investing.com Australia
Immunovant (NASDAQ:IMVT) Sets New 52-Week HighHere's What Happened - MarketBeat
Immunovant stock hits 52-week high at 28.32 USD - Investing.com
Precision Trading with Immunovant Inc. (IMVT) Risk Zones - Stock Traders Daily
Immunovant, Inc. (IMVT) Stock Analysis: Unpacking A 51% Potential Upside - DirectorsTalk Interviews
IMVT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? - AOL.com
Assessing Immunovant (IMVT) Valuation As Shares Deliver A 25% One Year Return - Yahoo Finance
What are Immunovant Inc.’s earnings expectationsOil Prices & Risk Managed Investment Strategies - mfd.ru
Aberdeen Group plc Has $15.83 Million Stock Position in Immunovant, Inc. $IMVT - MarketBeat
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT) - PR Newswire
Immunovant, Inc. (NASDAQ:IMVT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Immunovant, Inc. (IMVT) Stock Analysis: A Biotech Play With 57.77% Potential Upside - DirectorsTalk Interviews
Will Immunovant Inc. stock recover faster than marketTrade Analysis Report & Stepwise Swing Trade Plans - mfd.ru
What are analysts’ price targets for Immunovant Inc.Quarterly Trade Report & Capital Efficient Trading Techniques - mfd.ru
Technical Reactions to IMVT Trends in Macro Strategies - Stock Traders Daily
Why hedge funds are buying Immunovant Inc. stockMarket Trend Summary & Real-Time Volume Spike Alerts - mfd.ru
FY2026 EPS Forecast for Immunovant Increased by Analyst - MarketBeat
FY2030 EPS Estimates for Immunovant Raised by HC Wainwright - MarketBeat
Is now the right time to enter Immunovant Inc.Weekly Gains Report & Trade Opportunity Analysis Reports - mfd.ru
Immunovant shares climb 7% as fiscal Q3 loss comes in better than expected - MSN
Immunovant (IMVT) Gets a Buy from Oppenheimer - The Globe and Mail
Immunovant (NASDAQ:IMVT) Given Buy Rating at HC Wainwright - MarketBeat
Immunovant stock hits all-time high at 27.87 USD By Investing.com - Investing.com Australia
Immunovant Rides Brepocitinib Momentum Into 2026 - TipRanks
IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus - Finviz
Immunovant stock hits all-time high at 27.87 USD - Investing.com
Immunovant (NASDAQ:IMVT) Hits New 12-Month High After Earnings Beat - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Immunovant (IMVT) and Roivant Sciences (ROIV) - The Globe and Mail
All You Need to Know About Immunovant (IMVT) Rating Upgrade to Buy - MSN
A Look At Immunovant (IMVT) Valuation After Trial Progress Updates And Extended Cash Runway - Yahoo Finance
Immunovant, Inc. (NASDAQ:IMVT) Q3 2026 Earnings Call Transcript - Insider Monkey
Immunovant Inc (IMVT) Shares Surge 12.4% on Q3 Earnings Beat, Pipeline Milestones - AlphaStreet News
Decoding Immunovant Inc (IMVT): A Strategic SWOT Insight - GuruFocus
Does Immunovant’s (IMVT) Narrower Quarterly Per‑Share Loss Reframe Its Long‑Term Risk‑Reward Equation? - simplywall.st
Earnings call transcript: Immunovant beats Q3 2026 EPS expectations, stock surges - Investing.com Nigeria
Immunovant (NASDAQ:IMVT) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS - MarketBeat
Earnings call transcript: Immunovant beats Q3 2026 EPS expectations, stock surges By Investing.com - Investing.com South Africa
Immunovant (IMVT) Q2 2025 Earnings Call Transcript - AOL.com
IMVT: Brepocitinib delivered strong phase 2 efficacy in cutaneous sarcoidosis, advancing to phase 3 - TradingView
Immunovant (NASDAQ:IMVT) Shares Gap Up Following Strong Earnings - MarketBeat
Immunovant Q3 Earnings Call Highlights - MarketBeat
IMVT: Brepocitinib phase 2 data in cutaneous sarcoidosis showed 100% high-dose response and strong safety - TradingView
Immunovant Fiscal Q3 Loss Narrows; Shares Up Pre-Bell - marketscreener.com
Immunovant shares jump 7% as Q3 loss narrows, beats estimates - Investing.com Nigeria
Immunovant shares jump 7% as Q3 loss narrows, beats estimates By Investing.com - Investing.com Australia
IMMUNOVANT ($IMVT) Releases Q3 2026 Earnings - Quiver Quantitative
Immunovant Inc (IMVT) 財務データ
収益
当期純利益
現金流量
EPS
0.11%
6.00%
大文字化:
|
ボリューム (24 時間):